New drug progress | fourth adaptation!Junshi Biological PD-1 monochromatic treatment of nasopharyngeal cancer in China

Home > Health

New drug progress | fourth adaptation!Junshi Biological PD-1 monochromatic treatment of nasopharyngeal cancer in China

2021-11-29 12:05:53 32 ℃

Recently, PD-1 inhibitors developed by Junli

Tripili

(Duoyan) New indications have been approved, and new indications approved are:

Tripili combined withdrawal treatment for recurrent metastatic nasopharyngeal carcinoma (NPC) of the late line unhesed systemic treatment.

This is also the fourth indication of Tripili combined in China after melanoma, nasopharyngeal carcinoma (three-wire treatment) and urinary tract.

The new indication of this Tripili anti-batch is mainly based on Jupiter-02. This is a 3-phase clinical study of random, double blind, placebo controls, and international multi-center research. Study, 289 patients with RM-NPC without chemotherapy were allocated to Tripilic single according to the ratio of 1: 1 Anti-(240 mg, Q3W) combined with GP chemotherapy (Gemstitari and Cisplatin) group (n = 146) or placebo combined GP chemotherapy group (n = 143) received treatment, up to 6 cycles, continue to accept Tenoprie Anti-(Q3W) or placebo is maintained until the progression of disease progresses, or the non-tolerant toxicity, withdrawing informed consent or treatment has reached 2 years.

Tripili single anti-injection is the first domestic PD-1 target, which is approved by my country, approved a single anti-drug, approved first indications for uneven or metastasis of uneasiness that uneasses in the treatment of systemic systems. Treatment of sexual melanoma. In December 2020, Tripili combined anti-success through national medical insurance negotiations and was included in the new catalog.

Previously, Junshi Biology has announced Tripili comb to treat esophageal cancer (EC) to obtain Orphan Media for Orphan Medicine (OPHAN-DRUG DESIGNATION). This is the fourth orphanical disqualification of Tripri monocontrol, the prior to Tripili monochroma treatment of mucosal melanoma, nasopharyngeal carcinoma and soft tissue sarcoma have obtained FDA orpherical drug qualification. Today, Tripili monophydratica has started clinical research and development in early 2016, which has carried out more than 15 clinical studies covering more than 15 indications.

Reference:

[1] https://view.inews.qq.com/a/20211127a00wpa00